 Hey, I want to invite you to join Stocktwits. It’s the largest global community of active traders. You’ll get access to the real-time market insights, news, discussion and much more! You can sign up using my unique link below 
 


 has invited you to join Stocktwits

Two independent radiolabeling studies showed a 2.5- to 4.7-fold increase in tumor tissue with mIL12-FHAB, the mouse version of SON1010, compared with mIL-12 aloneAccumulation was observed in tumors...

Sonnet BioTherapeutics Announces Results of Biodistribution Studies Demonstrating Solid Tumor Targeting Using the FHAB Technology

PRINCETON, NJ / ACCESSWIRE / September 19, 2023 / Sonnet BioTherapeutics Holdings, Inc., (NASDAQ:SONN) a clinical-stage company developing targeted immunotherapeutic drugs, announced today that it...

Sonnet BioTherapeutics Regains Nasdaq Minimum Bid Price Compliance

Sonnet BioTherapeutics Holdings, Inc. (NASDAQ:SONN  Free Report)  Stock analysts at Chardan Capital upped their FY2023 earnings per share (EPS) estimates for Sonnet BioTherapeutics in a note issued to investors on Wednesday, August 16th. Chardan Capital analyst K. Nakae now forecasts ...

FY2023 EPS Estimates for Sonnet BioTherapeutics Holdings, Inc. (NASDAQ:SONN) Lifted by Analyst

Sonnet BioTherapeutics Holdings, Inc. (NASDAQ:SONN  Free Report)  Equities researchers at Chardan Capital issued their FY2024 earnings per share estimates for shares of Sonnet BioTherapeutics in a research report issued on Wednesday, August 16th. Chardan Capital analyst K. Nakae ...

Equities Analysts Offer Predictions for Sonnet BioTherapeutics Holdings, Inc.'s FY2024 Earnings (NASDAQ:SONN)

An IND was required to conduct the SB221 study of platinum-resistant ovarian cancer (PROC) with the combination of Sonnet's SON-1010 and Roche's atezolizumab (Tecentriq&reg;) in the USAs part of...

Sonnet BioTherapeutics Announces FDA Acceptance of the Company's IND for the SB221 Clinical Trial of SON-1010 Combined with Atezolizumab in the US

Combination study of SON-1010 with Roche's atezolizumab (Tecentriq&reg;) has been initiated in AustraliaFirst SON-1010 Phase 1 study has been completed and comparison of the human pharmacokinetic data supports targeting of tumor tissueEarly safety data from the SON-080 trial in CIPN is expected...

Sonnet BioTherapeutics Provides Fiscal Year 2023 Third Quarter Business and Earnings Update

Sonnet BioTherapeutics Holdings, Inc. (NASDAQ:SONN  Free Report) saw a significant drop in short interest in the month of June. As of June 15th, there was short interest totalling 2,040,000 shares, a drop of 24.2% from the May 31st total of 2,690,000 shares. Based on an average daily volume ...

Sonnet BioTherapeutics Holdings, Inc. (NASDAQ:SONN) Short Interest Down 24.2% in June

EF Hutton analyst Michael King reiterated a Buy rating on Sonnet BioTherapeutics Holdings (SONN Research Report) today and set a price target of ... EF Hutton analyst Michael King reiterated a Buy rating on Sonnet BioTherapeutics Holdings (SONN &#8211...

Sonnet BioTherapeutics Holdings (SONN) Receives a Buy from EF Hutton

PRINCETON, NJ / ACCESSWIRE / June 23, 2023 / Sonnet BioTherapeutics Holdings, Inc. (NASDAQ:SONN) ('Sonnet' or the 'Company'), a biopharmaceutical company developing innovative targeted biologic drugs, announced today that John Cini, PhD, Chief Scientific Officer and Co-Founder...

Sonnet BioTherapeutics Announces Presentations at the 2023 Cytokine-Based Drug Development Summit and Provides Preliminary Update on the SON-080 Study in Chemotherapy-Induced Peripheral Neuropathy

Sonnet BioTherapeutics Holdings, Inc. is a clinical stage biotechnology company, which engages in the innovation of biologic medicines. Its Fully Human Albumin Binding (FHAB) technology utilizes a single chain antibody fragment that binds to and hitch-hikes on human serum albumin for transport to target tissues. Its pipeline focuses on cytokines, a class of cell signaling peptides that, among other important functions, serve as potent immunomodulatory agents. The company was founded in 2011 and is headquartered in Princeton, NJ.

Watchers	23,665
52-Wk Low	$2.81
52-Wk High	$66.00

Market Cap	$5M
Volume (M)	14,960.00
52-Wk High	$66.00
52-Wk Low	$2.81

SONN Sonnet BioTherapeutics Holdings Inc

About

Feed

News

Sentiment

Earnings

Fundamentals